Nuclear detection of Y-boxprotein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer

Table 1 Clinico-pathological and immunohistochemical parameters in relation to YB-1 immunoreactivity, and univariate analysis of factors regarding tumor-related and recurrence-free surival

Variable	Categorization	Nuclear YB-1 immunoreactivity				Tumor-related death			Tumor recurrence
		n analyzable	neg.	pos.	p*	n	events	p^†	n	events	p^†
*Clinico-pathological data:*
Age at diagnosis
	<50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895
	≥ 50 years	108	74	34		108	45		102	42
Tumor stage
	pT1	40	35	5	0.004	40	4	<0.0001	39	5	0.0001
	pT2	83	63	20		83	28		81	34
	pT3	10	4	6		10	4		9	4
	pT4	26	15	11		26	18		24	15
Lymph node status
	pN0	75	60	15	0.101	75	11	<0.0001	74	13	<0.0001
	pN1-3	80	54	26		80	41		76	42
Histologic grade
	G1	17	16	1	0.011	17	4	0.0047	17	4	<0.0001
	G2	69	55	14		69	17		65	16
	G3	73	46	27		73	33		71	38
Multifocality
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683
	multifocal tumor	18	13	5		18	9		17	9
Histologic type
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730
	lobular	16	11	5		16	5		14	4
	other	15	10	5		15	5		13	4
*Immunohistochemistry (IHC):*
Estrogen receptor status
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026
	positive	96	69	27		96	25		92	27
Progesterone receptor status
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019
	positive	46	41	5		46	8		46	9
Cytokeratin 5/6 IHC
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349
	positive (1+-3+)	41	32	9		41	20		39	20
TP53 IHC
	<10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422
	≥ 10%	48	31	17		48	18		46	19
HER2 IHC
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008
	positive (2+-3+)	35	21	14		35	18		35	20

ISSN: 1471-2407